WO2026040323A1 - Monododécyl sulfate d'ibrutinib, son procédé de préparation et son utilisation - Google Patents

Monododécyl sulfate d'ibrutinib, son procédé de préparation et son utilisation

Info

Publication number
WO2026040323A1
WO2026040323A1 PCT/CN2025/074163 CN2025074163W WO2026040323A1 WO 2026040323 A1 WO2026040323 A1 WO 2026040323A1 CN 2025074163 W CN2025074163 W CN 2025074163W WO 2026040323 A1 WO2026040323 A1 WO 2026040323A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibrutinib
sulfate
monolaurate
preparation
good solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/074163
Other languages
English (en)
Chinese (zh)
Inventor
叶勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Talent Bio Pharmaceutical Technology Co Ltd
Original Assignee
Chengdu Talent Bio Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Talent Bio Pharmaceutical Technology Co Ltd filed Critical Chengdu Talent Bio Pharmaceutical Technology Co Ltd
Publication of WO2026040323A1 publication Critical patent/WO2026040323A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/02—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C305/04—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé cristallin de monododécyle sulfate d'ibrutinib, son procédé de préparation et son utilisation. La formule développée du composé cristallin est telle que représentée par la formule II. Le monododécyle sulfate d'ibrutinib est un composé cristallin ou un composé amorphe, et le composé cristallin est présent sous une forme anhydre et sans solvant. Le composé cristallin assure une bonne pharmacopotentialité de l'ibrutinib et améliore également de manière significative sa biodisponibilité pendant l'absorption orale ; de plus, le composé cristallin est également favorable à la réduction de la différence de l'effet de l'ibrutinib avant et après les repas, ce qui permet de réduire les réactions gastro-intestinales et la toxicité potentielle et les effets secondaires.
PCT/CN2025/074163 2024-08-23 2025-01-23 Monododécyl sulfate d'ibrutinib, son procédé de préparation et son utilisation Pending WO2026040323A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202411167700.X 2024-08-23
CN202411167700.XA CN121591740A (zh) 2024-08-23 2024-08-23 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用

Publications (1)

Publication Number Publication Date
WO2026040323A1 true WO2026040323A1 (fr) 2026-02-26

Family

ID=98864281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/074163 Pending WO2026040323A1 (fr) 2024-08-23 2025-01-23 Monododécyl sulfate d'ibrutinib, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN121591740A (fr)
WO (1) WO2026040323A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184572A1 (fr) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN112423757A (zh) * 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184572A1 (fr) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN112423757A (zh) * 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物

Also Published As

Publication number Publication date
CN121591740A (zh) 2026-03-03

Similar Documents

Publication Publication Date Title
CN104736526B (zh) 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
CN105121434B (zh) 坎格列净一水合物及其晶型、它们的制备方法和用途
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
WO2016155670A1 (fr) Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation
US11236077B2 (en) Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
US20170226119A1 (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
US10377725B2 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CN103664890B (zh) 喹啉衍生物的结晶及制备方法
WO2026040323A1 (fr) Monododécyl sulfate d'ibrutinib, son procédé de préparation et son utilisation
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN105228988B (zh) 曲格列汀半琥珀酸盐的晶体及其制备方法和药物组合物
WO2022087763A1 (fr) Co-cristal contenant une base libre de sorafénib et du 5-fluorouracile, composition pharmaceutique et leurs utilisations
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2011027988A2 (fr) Nouvelle forme polymorphe de l'hydrogénosulfate de prasugrel
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
WO2022253261A1 (fr) Forme cristalline d'hydrate de méthanesulfonate de lazertinib, son procédé de préparation et son utilisation
JP2026513056A (ja) 新規トリメタジジン固相
WO2013010502A1 (fr) Sel d'addition d'acide de prasugrel, son procédé de préparation et utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25855503

Country of ref document: EP

Kind code of ref document: A1